The pharma industry briefing

The latest news, approvals and clinical trials you need to know about this month

Data:
News in Numbers

Data: News in Numbers

15

Novartis has promised 15 generic and over-the-counter medicines at zero profit to developing countries during the pandemic

10%

- The US health department has reportedly agreed to buy 500,000 doses of remdesivir for use in US hospitals.

500,000

$215.8m

South Carolina-based generics maker Nephron Pharmaceuticals will pump $215.8 million into its vaccine fill-finish capacity and warehousing space as part of an expansion effort in the state.

3.4%

The Home Office has reported a decline in the number of scientific procedures carried out on living animals in UK labs in 2019.

$1.6bn

The US Government has committed $1.6bn in funding to late-stage biotech company Novavax for the accelerated development of its investigational coronavirus vaccine.

Data: News in Numbers

15

Novartis has promised 15 generic and over-the-counter medicines at zero profit to developing countries during the pandemic

500,000

The US health department has reportedly agreed to buy 500,000 doses of remdesivir for use in US hospitals.

3.4%

The Home Office has reported a decline in the number of scientific procedures carried out on living animals in UK labs in 2019.

$215.8m

South Carolina-based generics maker Nephron Pharmaceuticals will pump $215.8 million into its vaccine fill-finish capacity and warehousing space as part of an expansion effort in the state.

$1.6bn

The US Government has committed $1.6bn in funding to late-stage biotech company Novavax for the accelerated development of its investigational coronavirus vaccine.

UK '95% sure' Russian hackers tried to steal coronavirus vaccine research

The UK security minister James Brokenshire has said Britain is “more than 95%” sure that Russian state-sponsored hackers targeted UK, US and Canadian organisations involved in developing a coronavirus vaccine.disorder in combination with psychotherapy is mounting.

Source: The Guardian

FDA finalises bacterial pneumonia drug development guidances

The US Food and Drug Administration (FDA) has finalised two guidances on developing drugs to treat community-acquired or hospital-acquired and ventilator-associated bacterial pneumonia.

Source: Regulatory Affairs Professionals Society

UK launches clinical trial platform to accelerate Covid-19 drug development

The AGILE platform is a collaboration between the University of Liverpool, the Liverpool School of Tropical Medicine, and the Southampton Clinical Trials Unit that aims to speed up drug development in a pandemic situation without compromising patient safety.

Source: Labiotech

UK researchers engineer antibodies from llamas against Covid-19

Researchers from the Rosalind Franklin Institute, Oxford University, Diamond Light Source and Public Health England in the UK have engineered antibodies obtained from llamas against Covid-19.

Source: Pharmaceutical Technology

Approvals

Rukobia (fostemsavir) Extended-Release Tablets

The US Food and Drug Administration (FDA) has approved Rukobia for use in combination with other antiretrovirals for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection mellitus.

Source: ViiV Healthcare

Coronavir

Pharmaceutical company R-Pharm has secured regulatory approval in Russia for the use of its antiviral drug Coronavir, to treat patients suffering from Covid-19.

Source: Pharmaceutical Technology

NERLYNX (neratinib)

Malaysia’s Drug Control Agency has granted marketing approved for NERLYNX, an oral medication taken by women with breast cancer who have had surgery, chemotherapy and prior trastuzumab-based therapy.

Source: Puma Biotechnology